Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers

A randomized, controlled, open-label, multicenter study

Archana Chatterjee, Catherine O'Keefe, Meera Varman, Nicola P. Klein, Stephen Luber, Antigona Tomovici, Fernando Noriega

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Pentavalent and quadrivalent combination vaccine formulations from the same manufacturer (DTaP-IPV/Hib [PENTA], DTaP-IPV [QUAD]) were investigated as to whether they were sufficiently interchangeable to tailor use to local preference or availability. Methods: A randomized, controlled, open-label, 4-armed, multicenter study in healthy, full-term infants (42-89 days of age) was conducted in 38 centers across the United States. Participants were randomized 1:1:1:1 to a control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib) and 3 combination vaccine groups: (1) 3 doses PENTA, then Dose 4 DTaP and Hib; (2) 4 QUAD doses and Hib; (3) 4 PENTA doses. Participants (. N=. 2167) were immunized at 2, 4, and 6 months of age, Dose 4 participants (. N=. 1832) at 15 months of age. Immunogenicity was assessed before Doses 1 and 4 and after Doses 3 and 4. Safety was assessed 30 days after each dose and through 180 days Post-Dose 4. Results: Antibody responses and geometric mean concentrations/geometric mean titers (GMCs/GMTs) elicited by each combination vaccine were noninferior (upper-bound 90% confidence interval of GMC/GMT ratios

Original languageEnglish
Pages (from-to)3360-3368
Number of pages9
JournalVaccine
Volume30
Issue number23
DOIs
StatePublished - May 14 2012

Fingerprint

Acellular Vaccines
toddlers
Pertussis Vaccine
Haemophilus influenzae type b
Multicenter Studies
Combined Vaccines
immune response
vaccines
Safety
dosage
Antibody Formation
Vaccines
Confidence Intervals
Control Groups
PENTA
confidence interval

All Science Journal Classification (ASJC) codes

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers : A randomized, controlled, open-label, multicenter study. / Chatterjee, Archana; O'Keefe, Catherine; Varman, Meera; Klein, Nicola P.; Luber, Stephen; Tomovici, Antigona; Noriega, Fernando.

In: Vaccine, Vol. 30, No. 23, 14.05.2012, p. 3360-3368.

Research output: Contribution to journalArticle

@article{860731d8d3864f739e8711c87e2ac322,
title = "Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study",
abstract = "Background: Pentavalent and quadrivalent combination vaccine formulations from the same manufacturer (DTaP-IPV/Hib [PENTA], DTaP-IPV [QUAD]) were investigated as to whether they were sufficiently interchangeable to tailor use to local preference or availability. Methods: A randomized, controlled, open-label, 4-armed, multicenter study in healthy, full-term infants (42-89 days of age) was conducted in 38 centers across the United States. Participants were randomized 1:1:1:1 to a control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib) and 3 combination vaccine groups: (1) 3 doses PENTA, then Dose 4 DTaP and Hib; (2) 4 QUAD doses and Hib; (3) 4 PENTA doses. Participants (. N=. 2167) were immunized at 2, 4, and 6 months of age, Dose 4 participants (. N=. 1832) at 15 months of age. Immunogenicity was assessed before Doses 1 and 4 and after Doses 3 and 4. Safety was assessed 30 days after each dose and through 180 days Post-Dose 4. Results: Antibody responses and geometric mean concentrations/geometric mean titers (GMCs/GMTs) elicited by each combination vaccine were noninferior (upper-bound 90{\%} confidence interval of GMC/GMT ratios",
author = "Archana Chatterjee and Catherine O'Keefe and Meera Varman and Klein, {Nicola P.} and Stephen Luber and Antigona Tomovici and Fernando Noriega",
year = "2012",
month = "5",
day = "14",
doi = "10.1016/j.vaccine.2012.03.057",
language = "English",
volume = "30",
pages = "3360--3368",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23",

}

TY - JOUR

T1 - Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers

T2 - A randomized, controlled, open-label, multicenter study

AU - Chatterjee, Archana

AU - O'Keefe, Catherine

AU - Varman, Meera

AU - Klein, Nicola P.

AU - Luber, Stephen

AU - Tomovici, Antigona

AU - Noriega, Fernando

PY - 2012/5/14

Y1 - 2012/5/14

N2 - Background: Pentavalent and quadrivalent combination vaccine formulations from the same manufacturer (DTaP-IPV/Hib [PENTA], DTaP-IPV [QUAD]) were investigated as to whether they were sufficiently interchangeable to tailor use to local preference or availability. Methods: A randomized, controlled, open-label, 4-armed, multicenter study in healthy, full-term infants (42-89 days of age) was conducted in 38 centers across the United States. Participants were randomized 1:1:1:1 to a control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib) and 3 combination vaccine groups: (1) 3 doses PENTA, then Dose 4 DTaP and Hib; (2) 4 QUAD doses and Hib; (3) 4 PENTA doses. Participants (. N=. 2167) were immunized at 2, 4, and 6 months of age, Dose 4 participants (. N=. 1832) at 15 months of age. Immunogenicity was assessed before Doses 1 and 4 and after Doses 3 and 4. Safety was assessed 30 days after each dose and through 180 days Post-Dose 4. Results: Antibody responses and geometric mean concentrations/geometric mean titers (GMCs/GMTs) elicited by each combination vaccine were noninferior (upper-bound 90% confidence interval of GMC/GMT ratios

AB - Background: Pentavalent and quadrivalent combination vaccine formulations from the same manufacturer (DTaP-IPV/Hib [PENTA], DTaP-IPV [QUAD]) were investigated as to whether they were sufficiently interchangeable to tailor use to local preference or availability. Methods: A randomized, controlled, open-label, 4-armed, multicenter study in healthy, full-term infants (42-89 days of age) was conducted in 38 centers across the United States. Participants were randomized 1:1:1:1 to a control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib) and 3 combination vaccine groups: (1) 3 doses PENTA, then Dose 4 DTaP and Hib; (2) 4 QUAD doses and Hib; (3) 4 PENTA doses. Participants (. N=. 2167) were immunized at 2, 4, and 6 months of age, Dose 4 participants (. N=. 1832) at 15 months of age. Immunogenicity was assessed before Doses 1 and 4 and after Doses 3 and 4. Safety was assessed 30 days after each dose and through 180 days Post-Dose 4. Results: Antibody responses and geometric mean concentrations/geometric mean titers (GMCs/GMTs) elicited by each combination vaccine were noninferior (upper-bound 90% confidence interval of GMC/GMT ratios

UR - http://www.scopus.com/inward/record.url?scp=84859838560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859838560&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.03.057

DO - 10.1016/j.vaccine.2012.03.057

M3 - Article

VL - 30

SP - 3360

EP - 3368

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 23

ER -